Nektar Therapeutics (NKTR) Stock Price & How to Invest

Nektar Therapeutics is a San Francisco based, Nasdaq-listed clinical-stage biopharmaceutical company whose pipeline is anchored by rezpegaldesleukin (rezpeg), a first-in-class biologic designed to stimulate and expand regulatory T cells to restore immune balance. Nektar regained full rights to the molecule from Eli Lilly and is developing it across immuno-dermatology indications, with a Phase 2b program in moderate-to-severe atopic dermatitis (REZOLVE-AD, 393 patients), a Phase 2b program in severe-to-very-severe alopecia areata (REZOLVE-AA), and a Phase 2 study in type 1 diabetes. In February 2026 the company reported maintenance data from REZOLVE-AD showing durable and new responses on key disease measures with both monthly and quarterly dosing, and rezpeg holds FDA Fast Track designation in atopic dermatitis.

As a clinical-stage company, Nektar's income statement reflects development rather than commercial scale: Q1 2026 revenue was ~$10.9M (largely legacy royalties and collaboration-related items) against a net loss of ~$44.9M, with R&D the dominant expense. The business is funded by its balance sheet rather than product sales, and an April 2026 secondary offering lifted cash and investments to over ~$1B. Management has guided that pivotal Phase 3 trials in atopic dermatitis and alopecia areata would produce initial data readouts around 2028 with a potential BLA submission around 2029, which frames Nektar as a multi-year, catalyst-driven story rather than a near-term earnings play.

Nektar is pre-commercial, so it has no approved product revenue and continues to post operating losses funded by its balance sheet. Rezpegaldesleukin's pivotal outcomes are binary and years away (initial Phase 3 readouts guided around 2028), and clinical or regulatory setbacks could sharply affect the shares. The atopic dermatitis and alopecia areata markets are crowded with established biologics such as Dupixent and JAK inhibitors, so commercial success is not assured even with a positive trial. Additional capital raises could dilute existing holders, and the stock has historically been volatile around data and trial news.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Nektar Therapeutics's investor relations page or your broker.

• Share price: ~$74 (early July 2026)
• Market cap: ~$2.5B
• Q1 2026 revenue: ~$10.9M
• Q1 2026 net loss: ~$44.9M (~$1.82/share)
• Q1 2026 R&D expense: ~$35.7M
• Cash and investments: ~$1B (after April 2026 financing)

As a clinical-stage biopharma, Nektar carries no meaningful earnings, so traditional profit multiples do not apply and its value reflects the perceived probability and size of rezpegaldesleukin's opportunity. The ~$1B cash position is a large fraction of the ~$2.5B market cap, meaning much of the equity value is tied to pipeline expectations rather than current operations.

There are three common ways to get NKTR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so NKTR sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where NKTR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

The story is almost entirely about rezpegaldesleukin's path through Phase 3 and whether its Treg mechanism can carve out a place against entrenched biologics and JAK inhibitors. With over ~$1B in cash after an April 2026 financing, Nektar has runway to advance its programs, but pivotal readouts are years out (~2028) and outcomes are binary, so the shares tend to move sharply on data and trial news.

Whether NKTR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NKTR a buy?, and where the stock could go from here in the NKTR stock forecast.

For income investors, whether NKTR pays a dividend and how the payout looks is covered in does NKTR pay a dividend?